Image source: MannKind Corporation
What: It’s been a wild year for investors in MannKind Corp. (NASDAQ: MNKD), a biopharma focused on inhaled insulin drugs. The company’s share price has been all over the map, but it’s currently down by more than 28% since the start of 2016, according to data from S&P Global Market Intelligence.